Profile data is unavailable for this security.
About the company
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
- Revenue in SEK (TTM)27.73m
- Net income in SEK-248.31m
- Incorporated2000
- Employees47.00
- LocationAlligator Bioscience ABSCHEELEVAGEN 2 byggnad 401LUND 223 63SwedenSWE
- Phone+46 465408200
- Fax+46 462864290
- Websitehttps://alligatorbioscience.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xbrane Biopharma AB | 199.81m | -304.77m | 312.01m | 65.00 | -- | 1.20 | -- | 1.56 | -0.7304 | -0.9784 | 0.2266 | 0.1701 | 0.2309 | 0.4396 | 5.01 | 2,148,473.00 | -35.22 | -40.98 | -70.65 | -67.24 | 61.87 | -- | -152.53 | -364.40 | 0.8986 | -8.52 | 0.3957 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Medivir AB | 6.93m | -116.92m | 314.07m | 10.00 | -- | 2.21 | -- | 45.30 | -1.42 | -1.42 | 0.0735 | 1.26 | 0.0365 | -- | 1.31 | 693,300.00 | -61.49 | -28.91 | -81.28 | -34.77 | -1,300.04 | -467.42 | -1,686.46 | -675.96 | -- | -- | 0.0628 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Oncopeptides AB | 27.07m | -282.39m | 322.87m | 79.00 | -- | 2.38 | -- | 11.93 | -1.94 | -1.94 | 0.1763 | 0.6421 | 0.0882 | 0.8441 | 0.6929 | 474,929.80 | -91.96 | -141.28 | -107.34 | -200.49 | 89.97 | -- | -1,043.16 | -2,689.06 | 6.16 | -199.53 | 0.5030 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Thor Medical ASA | 0.00 | -18.26m | 325.70m | 1.00 | -- | 1.27 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Lytix Biopharma AS | 14.21m | -75.19m | 325.94m | 10.00 | -- | 5.60 | -- | 22.95 | -1.83 | -1.83 | 0.3454 | 1.19 | 0.1563 | -- | 1.42 | 1,444,300.00 | -82.70 | -56.91 | -103.61 | -65.83 | -- | -- | -529.29 | -771.78 | -- | -- | 0.0482 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -154.57m | 330.37m | 6.00 | -- | 1.95 | -- | -- | -4.25 | -4.25 | 0.00 | 4.10 | 0.00 | -- | -- | 0.00 | -62.70 | -125.17 | -70.31 | -151.70 | -- | -- | -- | -- | -- | -199.31 | 0.0084 | -- | -- | -- | -117.54 | -- | -- | -- |
| Saniona AB | 24.88m | -81.81m | 332.05m | 22.00 | -- | 47.89 | -- | 13.35 | -0.9821 | -0.9821 | 0.2822 | 0.0623 | 0.2386 | -- | 6.23 | 1,081,652.00 | -78.47 | -59.16 | -168.78 | -70.15 | -92.01 | -970.05 | -328.83 | -1,483.55 | -- | -3.03 | 0.8668 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Curasight A/S | -44.21m | -49.39m | 343.06m | 4.00 | -- | 17.39 | -- | -- | -1.51 | -1.51 | -1.35 | 0.6008 | -0.7563 | -- | -- | -7,107,500.00 | -84.49 | -24.61 | -111.31 | -26.01 | -- | -- | -- | -- | -- | -32.26 | 0.4439 | -- | -123.97 | -- | -42.62 | -- | -- | -- |
| Cantargia AB | 0.00 | -227.96m | 357.30m | 23.00 | -- | 3.89 | -- | -- | -1.29 | -1.29 | 0.00 | 0.4932 | 0.00 | -- | -- | 0.00 | -98.38 | -55.08 | -129.99 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -26.32m | 377.91m | 3.00 | -- | 13.61 | -- | -- | -0.4796 | -0.4796 | 0.00 | 0.5248 | 0.00 | -- | -- | 0.00 | -65.39 | -68.27 | -73.28 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -41.82m | 401.18m | 7.00 | -- | -- | -- | -- | -0.2756 | -0.2756 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -80.47 | -- | -97.51 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -104.57 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -141.42m | 503.60m | 28.00 | -- | 0.7211 | -- | -- | -3.54 | -3.54 | 0.00 | 13.87 | 0.00 | -- | -- | 0.00 | -21.08 | -18.84 | -23.01 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0318 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Alligator Bioscience AB | 27.73m | -248.31m | 526.84m | 47.00 | -- | -- | -- | 19.00 | -0.3667 | -0.3667 | 0.0403 | -0.1001 | 0.201 | -- | 9.80 | 478,017.30 | -180.01 | -73.26 | -2,941.13 | -91.33 | -- | -- | -895.60 | -811.68 | -- | -27.01 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Promimic AB | 40.92m | -10.45m | 660.47m | 17.00 | -- | 9.31 | -- | 16.14 | -0.563 | -0.563 | 2.21 | 3.80 | 0.4828 | -3.88 | 3.92 | 2,406,824.00 | -12.33 | -24.89 | -14.16 | -29.25 | 104.60 | 101.23 | -25.54 | -89.47 | 4.51 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Intellego Technologies AB | 231.25m | 82.86m | 670.67m | 62.00 | 8.40 | 3.10 | 7.41 | 2.90 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Arcticzymes Technologies ASA | 106.41m | 6.89m | 690.17m | 68.00 | 100.53 | 2.20 | 54.02 | 6.49 | 0.1367 | 0.1367 | 2.10 | 6.24 | 0.3199 | 0.45 | 1.93 | 1,591,059.00 | 2.07 | 15.58 | 2.19 | 17.22 | 93.99 | 96.69 | 6.47 | 33.23 | 14.95 | -- | 0.0273 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
Data as of Nov 11 2024. Currency figures normalised to Alligator Bioscience AB's reporting currency: Swedish Krona SEK
3.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 30 Sep 2024 | 13.94m | 1.84% |
| E. �hman J :or Fonder ABas of 31 Dec 2023 | 6.53m | 0.86% |
| FCG Fonder ABas of 30 Sep 2024 | 2.58m | 0.34% |
| SEB Investment Management ABas of 30 Sep 2024 | 1.62m | 0.21% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 442.51k | 0.06% |
| Skandia Investment Management ABas of 30 Aug 2024 | 95.54k | 0.01% |
| Aramea Asset Management AGas of 30 Jun 2022 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
